CN1434725A - 两亲聚合物以及包含两亲聚合物的多肽结合物 - Google Patents

两亲聚合物以及包含两亲聚合物的多肽结合物 Download PDF

Info

Publication number
CN1434725A
CN1434725A CN00818964A CN00818964A CN1434725A CN 1434725 A CN1434725 A CN 1434725A CN 00818964 A CN00818964 A CN 00818964A CN 00818964 A CN00818964 A CN 00818964A CN 1434725 A CN1434725 A CN 1434725A
Authority
CN
China
Prior art keywords
lcrf
moiety
polymer
peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00818964A
Other languages
English (en)
Chinese (zh)
Inventor
N·N·埃克乌里贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOBECOS Inc
Nobex Corp
Original Assignee
NOBECOS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOBECOS Inc filed Critical NOBECOS Inc
Publication of CN1434725A publication Critical patent/CN1434725A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
CN00818964A 1999-12-13 2000-12-11 两亲聚合物以及包含两亲聚合物的多肽结合物 Pending CN1434725A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/459,443 1999-12-13
US09/459,443 US6638906B1 (en) 1999-12-13 1999-12-13 Amphiphilic polymers and polypeptide conjugates comprising same

Publications (1)

Publication Number Publication Date
CN1434725A true CN1434725A (zh) 2003-08-06

Family

ID=23824795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00818964A Pending CN1434725A (zh) 1999-12-13 2000-12-11 两亲聚合物以及包含两亲聚合物的多肽结合物

Country Status (18)

Country Link
US (2) US6638906B1 (US06638906-20031028-C00017.png)
EP (1) EP1237580A2 (US06638906-20031028-C00017.png)
JP (1) JP2003516366A (US06638906-20031028-C00017.png)
KR (1) KR20020068053A (US06638906-20031028-C00017.png)
CN (1) CN1434725A (US06638906-20031028-C00017.png)
AU (1) AU2087501A (US06638906-20031028-C00017.png)
BR (1) BR0016339A (US06638906-20031028-C00017.png)
CA (1) CA2394928A1 (US06638906-20031028-C00017.png)
CZ (1) CZ20021990A3 (US06638906-20031028-C00017.png)
HK (1) HK1049283A1 (US06638906-20031028-C00017.png)
HU (1) HUP0300133A2 (US06638906-20031028-C00017.png)
IL (1) IL150119A0 (US06638906-20031028-C00017.png)
MX (1) MXPA02005885A (US06638906-20031028-C00017.png)
NO (1) NO20022793L (US06638906-20031028-C00017.png)
PL (1) PL359174A1 (US06638906-20031028-C00017.png)
RU (1) RU2002118709A (US06638906-20031028-C00017.png)
WO (1) WO2001041812A2 (US06638906-20031028-C00017.png)
ZA (1) ZA200204603B (US06638906-20031028-C00017.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740661A (zh) * 2012-05-10 2014-04-23 江南大学 一种提高酶热稳定性的方法
CN103740659A (zh) * 2012-05-10 2014-04-23 江南大学 一种提高酶热稳定性的方法
CN106729735A (zh) * 2017-03-09 2017-05-31 国家纳米科学中心 一种pH敏感的多肽聚合物及其制备方法和应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1468116A2 (en) 2002-01-16 2004-10-20 Dynal Biotech ASA Method for isolating nucleic acids and protein from a single sample
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) * 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2544156C (en) * 2003-10-29 2012-07-10 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
US20070026383A1 (en) * 2005-07-15 2007-02-01 Quintessence Biosciences, Inc. Methods and compositions for extracting membrane proteins
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
PT2314609T (pt) * 2008-07-30 2017-03-06 Takeda Pharmaceuticals Co Derivado de metastina e sua utilização
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
US20140039158A1 (en) * 2012-07-25 2014-02-06 Belrose Pharma, Inc. Polymeric conjugates and methods of preparing the same
BR112020021134A2 (pt) * 2018-04-16 2021-03-23 Merck Patent Gmbh aditivos para formulações de proteínas para aprimorar estabilidade térmica
KR20240026573A (ko) * 2022-08-22 2024-02-29 부산대학교 산학협력단 폴리소르베이트-숙신산-카르니틴 복합체 및 이를 포함하는 생리활성 물질 또는 약물 전달용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0862631A1 (en) 1995-10-26 1998-09-09 The Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740661A (zh) * 2012-05-10 2014-04-23 江南大学 一种提高酶热稳定性的方法
CN103740659A (zh) * 2012-05-10 2014-04-23 江南大学 一种提高酶热稳定性的方法
CN103740661B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN103740659B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN106729735A (zh) * 2017-03-09 2017-05-31 国家纳米科学中心 一种pH敏感的多肽聚合物及其制备方法和应用
CN106729735B (zh) * 2017-03-09 2020-05-12 国家纳米科学中心 一种pH敏感的多肽聚合物及其制备方法和应用

Also Published As

Publication number Publication date
RU2002118709A (ru) 2004-02-27
HK1049283A1 (zh) 2003-05-09
KR20020068053A (ko) 2002-08-24
BR0016339A (pt) 2002-08-27
NO20022793D0 (no) 2002-06-12
WO2001041812A3 (en) 2002-03-21
CZ20021990A3 (cs) 2002-11-13
US20040092449A1 (en) 2004-05-13
IL150119A0 (en) 2002-12-01
JP2003516366A (ja) 2003-05-13
EP1237580A2 (en) 2002-09-11
NO20022793L (no) 2002-08-13
PL359174A1 (en) 2004-08-23
CA2394928A1 (en) 2001-06-14
HUP0300133A2 (en) 2003-05-28
ZA200204603B (en) 2003-11-26
US6638906B1 (en) 2003-10-28
MXPA02005885A (es) 2002-10-23
AU2087501A (en) 2001-06-18
WO2001041812A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
CN1434725A (zh) 两亲聚合物以及包含两亲聚合物的多肽结合物
KR101022577B1 (ko) 항원성이 감소한 중합체 콘쥬게이트, 이의 제조방법 및용도
US8129330B2 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU694919B2 (en) Conjugation-stabilized polypeptide compositions
AU2005224078B2 (en) Methods for increasing protein polyethylene glycol (PEG) conjugation
AU2005205867A1 (en) Transglutaminase mediated conjugation of peptides
JP2006510601A5 (US06638906-20031028-C00017.png)
JP2011184442A (ja) Ｉｌ−２１の誘導体
JP5703020B2 (ja) タンパク質を選択的に修飾するための組成物と方法
JP2004524020A (ja) 改良された成長ホルモン分子
JP2010536923A5 (US06638906-20031028-C00017.png)
JP2007533298A (ja) Ｉｌ−２１の誘導体
JP4237703B2 (ja) インスリン様成長因子結合タンパク質−４及びポリ（エチレングリコール）の接合体
JP2000191700A (ja) 持続型消化管運動ペプチド
AU2006200906A1 (en) Amphiphilic polymers and polypeptide conjugates comprising same
MX2011001167A (es) Conjugados peptido-polimero.
JP2011084559A (ja) 改変融合タンパク質
KR20070017494A (ko) 펩티드의 트랜스글루타미나아제 매개된 접합

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication